# EDGAR Filing Document

**Accession Number:** 0002071433
**File Stem:** 0001583648-25-000029
**Filing Date:** 2025-6
**Character Count:** 7177
**Document Hash:** 6ae77dfe7d25c9f95eba875ae71c8424
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001583648-25-000029.hdr.sgml**: 20250603

**ACCESSION NUMBER**: 0001583648-25-000029

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250527

**FILED AS OF DATE**: 20250603

**DATE AS OF CHANGE**: 20250603

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Kline Ashley Hartmann
- **CENTRAL INDEX KEY:** 0002071433

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37471
- **FILM NUMBER:** 251021695

**MAIL ADDRESS:**
- **STREET 1:** C/O PALVELLA THERAPEUTICS, INC.
- **STREET 2:** 125 STRAFFORD AVE, SUITE 360
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PALVELLA THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001583648
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 300784346
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 125 STRAFFORD AVE
- **STREET 2:** SUITE 360
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (484) 253-1461

**MAIL ADDRESS:**
- **STREET 1:** 125 STRAFFORD AVE
- **STREET 2:** SUITE 360
- **CITY:** WAYNE
- **STATE:** PA
- **ZIP:** 19087

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pieris Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20241213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PIERIS PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20141218

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Marika Inc.
- **DATE OF NAME CHANGE:** 20130805

## Ex-24

```

POWER OF ATTORNEY
      KNOW ALL BY THESE PRESENTS, that the undersigned
hereby constitutes and appoints , Wesley H. Kaupinen,
Matthew Korenberg and Kathleen A. McGowan of Pavella
Therapeutics, Inc.  ("the Company"), with full power to
act singly, as the undersigned's true and lawful
attorneys-in-fact, with full power of substitution, to:

        (1)     execute for and on behalf of the undersigned,
in the undersigned's capacity as an officer and/or
director and/or beneficial owner of the Company, Form ID
Application, Update Passphrase, Consent of Report Person,
Forms 3, 4, and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934 and the rules thereunder;
        (2)     do and perform any and all acts for an on
behalf of the undersigned which may be necessary or
desirable to complete and execute any such Form ID Application,
Update Passphrase, Consent of Reporting Person, Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and
timely file such form with the United States Securities and
Exchange Commission and any stock exchange or similar authority;
and
        (3)     take any other action of any type whatsoever in
connection with the foregoing which, in the opinion of
such attorneys-in-fact, may be of benefit to, in the best
interest of, or legally required by, the undersigned, it
being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant
to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorneys-
in-fact may approve in such attorney-in-fact's discretion.
        The undersigned hereby grants to such attorneys-in-
fact full power and authority to do and perform any and
every act and thing whatsoever requisite, necessary, or
proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if
personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers
herein granted.
        This Power of Attorney shall remain in full force
and effect until revoked by the undersigned in a signed
writing delivered to the attorney-in-fact.
        IN WITNESS WHEREOF, the undersigned has caused this
Power of Attorney to be executed as of this 28th day of May,
2025.

/s/ Ashley Kline
Ashley Kline

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Kline Ashley Hartmann<br><sub>(Last) (First) (Middle)</sub><br>C/O PALVELLA THERAPEUTICS, INC.<br>125 STRAFFORD AVENUE, SUITE 360<br><sub>(Street)</sub><br>WAYNE, PA 19087<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>PALVELLA THERAPEUTICS, INC. [ PVLA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-05-27 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Commercial Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Signature:** By: /s/ Kathleen A. McGowan For: Ashley Kline  
**Date:** 2025-05-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**